Tatemichi Satoshi, Kobayashi Kumi, Maruyama Itaru, Kobayashi Mamoru, Yamazaki Yoshinobu, Shibata Nobuo
Pharmacology Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Azumino City, Japan.
Yakugaku Zasshi. 2006 Mar;126 Spec no.:217-23. doi: 10.1248/yakushi.126.217.
The effects of silodosin, an alpha(1A)-adrenoceptor (AR) antagonist, and of other alpha(1)-AR antagonists on the phenylephrine (PE)-induced increase in intraurethral pressure (IUP) and on blood pressure (BP) were studied in anesthetized rats. The drugs were administered intravenously (i.v. study) or intraduodenally (i.d. study). IUP and BP were measured via catheters inserted into the prostatic urethra and common carotid artery, respectively. In the i.v. study, drugs were administered every 30 min for effects on BP, and 5 min before each PE-injection (30 microg/kg, every 60 min) with stepwise increases in dose for effects on IUP. In the i.d. study, one dose of drug was administered per rat, then IUP and BP were observed for 4 h [IUP being measured time-dependently following PE-injection (30 microg/kg)], and IUP and BP were expressed as a percentage of the values without any drugs. ID(50) for IUP and ED(15) for BP were calculated, and uroselectivity was determined as ED(15)/ID(50) for each drug. All drugs both inhibited the IUP increase and lowered BP, each effect being dose-dependent. The order of uroselectivities was silodosin (11.7)>tamuslosin (2.24)>naftopidil (0.133) in the i.v. study, and silodosin (26.0)>tamuslosin (3.82)>naftopidil (1.39) in the i.d. study. Selectivity for the lower urinary tract (LUT) was higher for silodosin than for tamsulosin (alpha(1A)/alpha(1D)-AR), naftopidil (alpha(1D)-AR), or prazosin (non-selective alpha(1)-AR). These results suggested that an alpha(1A)-AR selective antagonist like silodosin might be effective in the LUT without causing hypotension.
在麻醉大鼠中研究了α1A肾上腺素能受体(AR)拮抗剂西洛多辛及其他α1-AR拮抗剂对去氧肾上腺素(PE)诱导的尿道内压(IUP)升高及血压(BP)的影响。药物通过静脉注射(静脉注射研究)或十二指肠内给药(十二指肠内给药研究)。分别通过插入前列腺尿道和颈总动脉的导管测量IUP和BP。在静脉注射研究中,每30分钟给药一次以观察对BP的影响,在每次PE注射(30μg/kg,每60分钟一次)前5分钟给药,并逐步增加剂量以观察对IUP的影响。在十二指肠内给药研究中,每只大鼠给予一剂药物,然后观察IUP和BP 4小时[PE注射(30μg/kg)后随时间测量IUP],IUP和BP表示为无任何药物时数值的百分比。计算IUP的半数抑制剂量(ID50)和BP的15%有效剂量(ED15),并确定每种药物的尿道选择性为ED15/ID50。所有药物均抑制IUP升高并降低BP,每种效应均呈剂量依赖性。静脉注射研究中尿道选择性顺序为西洛多辛(11.7)>坦索罗辛(2.24)>萘哌地尔(0.133),十二指肠内给药研究中为西洛多辛(26.0)>坦索罗辛(3.82)>萘哌地尔(1.39)。西洛多辛对下尿路(LUT)的选择性高于坦索罗辛(α1A/α1D-AR)、萘哌地尔(α1D-AR)或哌唑嗪(非选择性α1-AR)。这些结果表明,像西洛多辛这样的α1A-AR选择性拮抗剂可能在下尿路有效而不引起低血压。